Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 10Meningioma 4Gastro-enteropancreatic neuroendocrine tumor 3Prostatic Neoplasms 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Germ Cell and Embryonal 2Medulloblastoma 2Glioma 2Ependymoma 2Adenoma, Islet Cell 2Stomach Neoplasms 1Sarcoma, Synovial 1Recurrence 1Pancreatic Diseases 1Osteosarcoma 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Intestinal Neoplasms 1Intestinal Diseases 1Hypertension 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Digestive System Neuroendocrine Tumor G1 × lutetium Lu 177 dotatate × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡